Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PMS2 Antibodies:
anti-Mouse (Murine) PMS2 Antibodies:
anti-Rat (Rattus) PMS2 Antibodies:
Go to our pre-filtered search.
Human Monoclonal PMS2 Primary Antibody for IF, IP - ABIN967525
Cleaver: It was a very good year for DNA repair. in Cell 1994
Show all 5 Pubmed References
Human Monoclonal PMS2 Primary Antibody for IF, IHC - ABIN4346521
Calegari, Inno, Monterisi, Orlandi, Santini, Basso, Cassano, Martini, Cenci, de Pascalis, Camarda, Barbaro, Larocca, Gori, Tonini, Barone: A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. in British journal of cancer 2017
A novel pathogenic PMS2 mutation in a mismatch repair deficiency patient
High PMS2 expression is associated with the development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
Data suggest that yeast Mlh1 (show MLH1 Antibodies)-Mlh3 (show MLH3 Antibodies) heterodimer does not exhibit hallmarks of a canonical (structure-selective) Holliday junction resolvase/endonuclease; multiple Mlh1 (show MLH1 Antibodies)-Mlh3 (show MLH3 Antibodies) heterodimers appear to load onto DNA to form an activated polymer that cleaves DNA; human MLH1 (show MLH1 Antibodies)-PMS2 exhibits similar characteristics. (MLH = mutL homolog protein; PMS2 = post meiotic segregation increased 2 protein)
In an individual with mismatch repair deficiency syndrome, PMS2 was found to be homozygously inactivated by a complex chromosomal rearrangement.
show that DNA repair genes (fan1 (show FSCN1 Antibodies) and pms2) significantly modify age at onset in Huntington's Disease and Spinocerebellar Ataxias, suggesting a common pathogenic mechanism, which could operate through the observed somatic expansion of repeats
The results of this case study indicated that although FOXL2 (show FOXL2 Antibodies) 402C > G mutation determines the development of granulosa cell tumor, PMS2 mutation may be the initial driver of carcinogenesis. Immunohistochemistry-based tumor testing for mismatch repair gene expression may be necessary for granulosa cell tumors to determine their malignant potential or if they are part of Lynch syndrome.
A total of 201 unique disease-predisposing mismatch repair gene mutations were identified in 369 Lynch syndrome families. These mutations affected MLH1 (show MLH1 Antibodies) in 40%, MSH2 (show MSH2 Antibodies) in 36%, MSH6 (show MSH6 Antibodies) in 18% and PMS2 in 6% of the families.
molecular mechanisms linking MMR (show MRC1 Antibodies) with chemoresistance and suggest that stabilization of PMS2 expression may be useful in overcoming the cisplatin resistance in EOC.
PMS2 mutation carriers with retention of RNA expression developed CRC (show CALR Antibodies) 9 years later than those with loss of RNA expression. If confirmed, this finding would justify a delay in surveillance for these cases. Cancer risk was not influenced by a parent-of-origin effect
Individuals who carry a MMR (show MRC1 Antibodies) gene (MLH1 (show MLH1 Antibodies), MSH2 (show MSH2 Antibodies), PMS2 or MSH6 (show MSH6 Antibodies)) mutation are at an increased risk of developing cancers at multiple sites, most notably colorectal and endometrial carcinomas.
Pms2/Mlh1 (show MLH1 Antibodies) and multiple uracil glycosylases act jointly, each one with a distinct strand bias, to enlarge the immunoglobulin gene mutation spectrum from G-C to A-T bases.
Primary function of Pms2 during spermatogenesis is to stabilize Mlh1 (show MLH1 Antibodies) levels prior to its critical crossing over function with Mlh3 (show MLH3 Antibodies). An intact Pms2 ATPase (show DNAH8 Antibodies) domain is not essential for male fertility.
Pms2 specifically suppresses large expansions of a pathogenic trinucleotide repeat sequence in neuronal tissues, possibly acting independently of the canonical mismatch repair pathway.
Down-regulation of PMS2 is associated with initiation and growth of neuroblastoma (show ARHGEF16 Antibodies) and brain tumour multicellular spheroids.
the integrity of the MLH1 (show MLH1 Antibodies) ATPase (show DNAH8 Antibodies) domain is more critical than the PMS2 ATPase (show DNAH8 Antibodies) domain for normal DNA mismatch repair functions
Data show that the PMS2 endonuclease activity has distinct biological functions and is essential for genome maintenance and tumor suppression.
Role for mismatch repair proteins Msh2 (show MSH2 Antibodies), Mlh1 (show MLH1 Antibodies), and Pms2 in immunoglobulin class switching shown by sequence analysis of recombination junctions.
We found that MLH1 (show MLH1 Antibodies) and PMS2 have functional nuclear localization signals (NLS (show ALDH1A2 Antibodies)) and nuclear export sequences, yet nuclear import depended on their C-terminal dimerization to form MutLalpha
Pms2 has a role in the prevention of tandem CC --> TT substitutions induced by ultraviolet radiation and oxidative stress.
Data show partial functional redundancy between MLH3 (show MLH3 Antibodies) and PMS2 orthologues for mutation avoidance and show a role for Mlh3 (show MLH3 Antibodies) in gastrointestinal and extragastrointestinal tumor suppression.
This gene is one of the PMS2 gene family members found in clusters on chromosome 7. The product of this gene is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Mutations in this gene are associated with hereditary nonpolyposis colorectal cancer, Turcot syndrome, and are a cause of supratentorial primitive neuroectodermal tumors. Alternatively spliced transcript variants have been observed for this gene.
mismatch repair endonuclease PMS2
, DNA mismatch repair protein PMS2
, PMS1 protein homolog 2
, PMS2 postmeiotic segregation increased 2